skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
BRAF Inhibitor PLX8394 (Code C113330)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: BRAF Inhibitor PLX8394

Definition: An orally bioavailable inhibitor of serine/threonine-protein kinase B-raf (BRAF) protein with potential antineoplastic activity. BRAF inhibitor PLX8394 appears to selectively bind to and inhibit the activity of both wild-type and mutated forms of BRAF, which may subsequently inhibit the proliferation of tumor cells which express mutated forms of BRAF. This inhibitor appears to be effective against tumors that express multiple mutated forms of the kinase and may be an effective therapeutic agent for tumors that are resistant to other BRAF inhibitor therapies that are specific for the BRAF V600E mutant. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of MAP kinase/ERK signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms of BRAF are associated with a number of neoplastic diseases.

Label: BRAF Inhibitor PLX8394

NCI Thesaurus Code: C113330 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3827086  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
BRAF Inhibitor PLX8394

External Source Codes: 
PDQ Closed Trial Search ID 756043
PDQ Open Trial Search ID 756043 (check for NCI PDQ open clinical trial info)
UMLS CUI C3827086

Other Properties:
     Name Value (qualifiers indented underneath)
code C113330
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom